Bluebird Bio Inc. (BLUE) Stock Rating Lowered by Cantor Fitzgerald

Bluebird Bio Inc. (NASDAQ:BLUE) was downgraded by Cantor Fitzgerald from a “hold” rating to a “sell” rating in a report released on Friday. They presently have a $37.00 price objective on the stock, down from their prior price objective of $65.24. Cantor Fitzgerald’s price target indicates a potential downside of 33.33% from the company’s current price.

A number of other equities analysts also recently issued reports on BLUE. Maxim Group set a $85.00 price target on Bluebird Bio and gave the stock a “buy” rating in a research report on Thursday, September 22nd. Leerink Swann reiterated an “outperform” rating and set a $67.00 price target on shares of Bluebird Bio in a research report on Thursday, August 4th. Wedbush reiterated an “outperform” rating and set a $117.00 price target on shares of Bluebird Bio in a research report on Wednesday, August 3rd. Vetr upgraded Bluebird Bio from a “buy” rating to a “strong-buy” rating and set a $44.44 price target on the stock in a research report on Monday, June 27th. Finally, Zacks Investment Research downgraded Bluebird Bio from a “hold” rating to a “sell” rating in a research report on Wednesday, October 5th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $91.60.

Analyst Recommendations for Bluebird Bio (NASDAQ:BLUE)

Bluebird Bio (NASDAQ:BLUE) opened at 55.50 on Friday. The stock’s market cap is $2.06 billion. Bluebird Bio has a one year low of $35.37 and a one year high of $99.70. The stock has a 50 day moving average price of $63.83 and a 200-day moving average price of $51.18.

Bluebird Bio (NASDAQ:BLUE) last issued its earnings results on Wednesday, August 3rd. The company reported ($1.59) EPS for the quarter, missing analysts’ consensus estimates of ($1.44) by $0.15. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. The company earned $1.55 million during the quarter, compared to analysts’ expectations of $2.01 million. During the same quarter in the previous year, the company earned ($1.57) EPS. The firm’s quarterly revenue was down 68.6% compared to the same quarter last year. Equities research analysts expect that Bluebird Bio will post ($6.19) earnings per share for the current fiscal year.

In other Bluebird Bio news, insider Eric Sullivan sold 416 shares of the firm’s stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $67.00, for a total transaction of $27,872.00. Following the completion of the sale, the insider now owns 5,891 shares of the company’s stock, valued at $394,697. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 3.50% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Seven Eight Capital LLC purchased a new position in Bluebird Bio during the first quarter valued at approximately $108,000. Quantbot Technologies LP raised its position in Bluebird Bio by 431.3% in the second quarter. Quantbot Technologies LP now owns 2,848 shares of the company’s stock valued at $123,000 after buying an additional 2,312 shares in the last quarter. First Mercantile Trust Co. purchased a new position in Bluebird Bio during the third quarter valued at approximately $129,000. BlackRock Inc. raised its position in Bluebird Bio by 341.0% in the first quarter. BlackRock Inc. now owns 4,569 shares of the company’s stock valued at $194,000 after buying an additional 3,533 shares in the last quarter. Finally, BNP Paribas Arbitrage SA raised its position in Bluebird Bio by 110.5% in the third quarter. BNP Paribas Arbitrage SA now owns 3,084 shares of the company’s stock valued at $209,000 after buying an additional 1,619 shares in the last quarter.

Bluebird Bio Company Profile

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

5 Day Chart for NASDAQ:BLUE

Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Michael Jordan Gains Ground on Getting His Name Back
Michael Jordan Gains Ground on Getting His Name Back
McDonald’s Keeping As Much As 25% in Hong Kong and China Stores
McDonald’s Keeping As Much As 25% in Hong Kong and China Stores
President Obama Take Steps to Block Chip Maker Acquisition by Chinese Company
President Obama Take Steps to Block Chip Maker Acquisition by Chinese Company
GoPro Planning to Cut 200 Jobs
GoPro Planning to Cut 200 Jobs
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Retailers Anticipating Strong Support for Small Business Saturday
Retailers Anticipating Strong Support for Small Business Saturday


 
© 2006-2016 Ticker Report. Google+.